Abstract: The present disclosure relates to compositions and methods for the treatment of TECPR2-associated diseases or disorders. Several embodiments provided for herein relate to virally-mediated transfer of a gene to target cells to induce expression of an encoded polypeptide, protein or other product in order to ameliorate one or more symptoms of a TECPR2-associated disease or disorder in a subject. In several embodiments, the disclosed methods and compositions relate to recombinant adeno-associated virus particles encoding human TECPR2 in order to treat TECPR2-associated diseases or disorders, including spastic paraplegic type 49 (SPG49) and/or hereditary sensory and autonomic neuropathy 9 (HSAN9).